key: cord-0859924-k0le99jq
authors: Stephens, Michael R.; Moore, Duncan F.; Dau, Jonathan; Jobbagy, Soma; Neel, Victor A.; Bolster, Marcy B.; Fedeles, Flavia
title: A case of generalized morphea profunda following SARS-CoV-2 infection
date: 2022-03-12
journal: JAAD Case Rep
DOI: 10.1016/j.jdcr.2022.02.033
sha: 54b75daaacd9d8e28a27fe21db86baa36690f509
doc_id: 859924
cord_uid: k0le99jq

nan

The authors of this manuscript have consented to its publication and have no conflicts of interest 23 to disclose. Patient consent: 29 The patient consented for the photographs and medical information to be published in print and 30 online and with the understanding that this information may be publicly available. Signed 31 consent form is on file. laboratory evaluation, and imaging were supportive of a diagnosis of morphea profunda. The 78 patient did have eosinophilia; however, this was chronic. The differential diagnosis included 79 eosinophilic fasciitis, but this was not favored based on clinical appearance and lack of fascial 80 thickening on biopsy. The patient was initially started on prednisone, which she stopped after a 81 few days due to concern for side effects. She also declined treatment with methotrexate and 82 mycophenolate mofetil due to potential side effects. She was eventually started on mycophenolic 83 acid (for better tolerability), but has not yet returned for follow-up. 

Localized 143 scleroderma associated with chronic hepatitis C

Postvaccination morphea profunda in a child

Case report: Systemic sclerosis after COVID-19 infection

Multisystemic cellular tropism of 150 SARS-COV-2 in autopsies of COVID-19 patients

Tocilizumab in hospitalized patients with severe 152 COVID-19 pneumonia

The role of IL-6 in skin 154 fibrosis and cutaneous wound healing

Serum interleukin 6 is predictive of early 156 functional decline and mortality in interstitial lung disease associated with systemic